Fundraising Fox㈱PRISM BioLab
Tokyo, JP · 3 known investors
Find your way into ㈱PRISM BioLab
Sign up to find every way you can get introduced to ㈱PRISM BioLab
- Your email: who you already know at ㈱PRISM BioLab, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the ㈱PRISM BioLab team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
PRISM BioLab is a biotechnology company that develops PepMetics, a proprietary drug discovery platform of small molecules designed to mimic α-helix or β-turn peptides, aiming to target proteins previously considered "undruggable." The company maintains a screening library of over 20,000 compounds and partners with pharmaceutical firms on drug discovery programs.
Investors · 3
DBJ Capitallisted by DBJ CapitalTokyo · $2.7M – $354M
How we know: DBJ Capital's portfolio page · Not right? Tell us
Newton Biocapitallisted by Newton BiocapitalBrussels
How we know: Newton Biocapital's portfolio page · the VCSheet dataset · Not right? Tell us
Frequently asked questions
- What does ㈱PRISM BioLab do?
- PRISM BioLab is a biotechnology company that develops PepMetics, a proprietary drug discovery platform of small molecules designed to mimic α-helix or β-turn peptides, aiming to target proteins previously considered "undruggable." The company maintains a screening library of over 20,000 compounds and partners with pharmaceutical firms on drug discovery programs.
- Who are ㈱PRISM BioLab's investors?
- ㈱PRISM BioLab's investors include DBJ Capital, Eisai Innovation, Inc., Newton Biocapital.
- Where is ㈱PRISM BioLab headquartered?
- ㈱PRISM BioLab is headquartered in Tokyo, JP.